Ondansetron Kabi (Ondansetron Hydrochloride Dihydrate)

Ondansetron Hydrochloride Dihydrate, the active ingredient in Ondansetron Kabi, is a 5-HT3 receptor antagonist presented as an intravenous solution for injection use. It helps prevent nausea and vomiting associated with chemotherapy, radiotherapy, and postoperative recovery in adult and pediatric patients.

GNH USA supplies Ondansetron Kabi as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, and pharmacies worldwide.

Ondansetron Kabi is a selective 5‑HT3 receptor antagonist used in the management of nausea and vomiting pathways related to several clinical settings. - Chemotherapy‑induced nausea and vomiting: Reduces the frequency and severity of acute and delayed episodes. - Radiotherapy‑induced nausea and vomiting: Helps control nausea during and after radiation treatment. - Post‑operative nausea and vomiting: Decreases the incidence of vomiting after surgical procedures. - Pregnancy‑associated hyperemesis gravidarum (off‑label): May be considered when conventional therapy fails.

Adverse reactions to Ondansetron Kabi are generally dose‑dependent and vary from mild to serious.

Common Side Effects: - Headache: mild to moderate intensity. - Constipation: occasional bowel movement reduction. - Diarrhoea: loose stools in a minority of patients. - Fatigue: feeling of tiredness or low energy. - Injection site pain: mild discomfort at the infusion site.

Serious or Rare Side Effects: - QT interval prolongation: may predispose to cardiac arrhythmias. - Severe hypersensitivity: rash, itching, swelling, or anaphylaxis. - Serotonin syndrome: rare but possible when combined with other serotonergic agents. - Hepatic enzyme elevation: abnormal liver function tests. - Vision changes: blurred vision or visual disturbances.

When using Ondansetron Kabi, clinicians should consider several safety aspects before and during therapy. - Cardiac monitoring: patients with known QT prolongation or electrolyte disturbances should have ECG monitoring. - Electrolyte balance: correct hypokalemia, hypomagnesemia, or hypocalcaemia before administration. - Concomitant serotonergic drugs: assess risk of serotonin syndrome. - Pregnancy and lactation: weigh    - Renal impairment: dose adjustment may be required in severe renal dysfunction. - Store at 2-8°C: keep refrigerated  

The intravenous formulation of  

Major